Jounce Therapeutics Inc. is intent on discovering new immune regulatory targets that it hopes will result in a large portfolio of antibody-based immunotherapies to treat many solid cancers.

Cancer immunotherapies typically induce T cells to attack and destroy a patient's tumor cells and thus extend survival. In principle, this could be accomplished by agonizing positive regulators of T cell activity or by inhibiting immune checkpoint proteins, which are negative regulators of T cell activity.